When will the ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER patents expire, and when will generic ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER be available?

Sponsor	Phase
University of New Mexico	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; potassium chloride; sodium acetate; sodium chloride	INJECTABLE;INJECTION	019864-001	Jun 10, 1993		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is a parenteral fluid utilized for hydration and electrolyte replenishment. Its market trajectory is influenced by demand in hospital settings, surgical procedures, and critical care. The financial performance of products in this segment is closely tied to reimbursement policies, supply chain stability, and competition from generics and alternative formulations.

What is the therapeutic class and primary indication for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER belongs to the class of intravenous solutions. Its primary indication is for the restoration and maintenance of the extracellular fluid volume and providing hydration. It is specifically used as a source of electrolytes and calories. The formulation includes dextrose, which provides caloric energy, and a balanced mix of electrolytes such as sodium, potassium, chloride, and acetate, to address fluid and electrolyte imbalances. These imbalances can arise from various clinical conditions including dehydration, surgical fluid losses, and nutritional support in patients unable to take oral fluids.

Who are the key manufacturers and suppliers of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

The market for intravenous solutions like ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is characterized by a limited number of large-scale manufacturers and suppliers due to the stringent regulatory requirements for sterile product manufacturing. Key players often include multinational pharmaceutical and medical device companies with established sterile manufacturing capabilities and extensive distribution networks.

While specific market share data can fluctuate, companies that are significant suppliers of intravenous solutions globally and in major markets like the United States include:

Baxter International Inc. Baxter is a prominent supplier of intravenous solutions, including electrolyte and dextrose combinations, for hospital and healthcare settings.
Fresenius Kabi AG. This company is a global provider of infusion therapy, IV drugs, and clinical nutrition products. They manufacture and distribute a wide range of IV fluids.
B. Braun Melsungen AG. B. Braun is another major player in the healthcare market, offering a comprehensive portfolio of IV therapy products, including parenteral solutions.

These companies operate large-scale manufacturing facilities compliant with Good Manufacturing Practices (GMP) and maintain robust supply chains to ensure product availability. The production of sterile parenteral solutions requires specialized infrastructure and adherence to strict quality control measures.

What is the global market size and projected growth rate for parenteral fluid solutions?

The global market for parenteral fluid solutions is substantial and is expected to continue growing. This growth is driven by an increasing incidence of chronic diseases, a rising volume of surgical procedures, and the expanding healthcare infrastructure in emerging economies.

According to market research reports, the global parenteral fluid market size was valued at approximately USD 11.2 billion in 2023 [1]. The market is projected to expand at a compound annual growth rate (CAGR) of 4.5% to 5.5% from 2024 to 2030. By 2030, the market is anticipated to reach a value of approximately USD 15.0 billion to USD 17.0 billion.

Key drivers for this market expansion include:

Aging Population: An increase in the elderly population worldwide leads to a higher prevalence of conditions requiring intravenous fluid therapy.
Surgical Procedures: The growing number of elective and emergency surgeries globally increases the demand for perioperative fluid management.
Chronic Disease Management: Patients with conditions such as diabetes, kidney disease, and cardiovascular disorders often require intravenous fluid support.
Emerging Markets: Expanding healthcare access and infrastructure in regions like Asia-Pacific and Latin America are contributing to market growth.
Technological Advancements: Innovations in drug delivery systems and improved manufacturing processes also support market expansion.

The specific segment for dextrose-based electrolyte solutions like ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER contributes significantly to this overall market.

What are the primary market drivers and restraints for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

The market dynamics for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER are influenced by several factors, both driving demand and posing challenges.

Market Drivers:

Hospital and Institutional Demand: The primary consumers are hospitals, clinics, and long-term care facilities. Increased patient admissions, particularly for critical care, surgery, and emergency services, directly translate to higher demand for intravenous fluids. The COVID-19 pandemic, for instance, led to a surge in demand for such solutions due to hospitalization rates.
Surgical and Procedural Volume: A rising number of surgical procedures, from routine operations to complex interventions, necessitates adequate fluid and electrolyte management. ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is often used in perioperative settings to maintain hydration and electrolyte balance.
Prevalence of Dehydration and Electrolyte Imbalances: Conditions such as gastrointestinal disorders (vomiting, diarrhea), burns, and certain medical treatments can lead to significant fluid and electrolyte loss, making these solutions critical for patient recovery.
Nutritional Support: The dextrose component provides a source of calories, making it useful in patients who are unable to consume adequate nutrition orally or enterally. This is particularly relevant in intensive care units.
Cost-Effectiveness and Availability: Compared to more complex nutritional or therapeutic intravenous formulations, basic electrolyte and dextrose solutions are generally cost-effective and widely available, making them a staple in healthcare settings.
Established Clinical Protocols: The use of these solutions is well-established in clinical practice, with extensive guidelines and protocols supporting their administration for various indications.

Market Restraints:

Competition: The market for basic intravenous solutions is competitive. Multiple manufacturers produce similar products, leading to price pressures. Generic competition can erode profit margins for branded products.
Reimbursement Policies and Payer Scrutiny: Healthcare reimbursement policies can impact pricing and market access. Payers, including government programs and private insurers, may scrutinize the necessity and cost-effectiveness of intravenous fluid administration, potentially limiting coverage or mandating preferred products.
Supply Chain Vulnerabilities: The manufacturing of sterile parenteral products is complex and relies on a stable supply of raw materials (dextrose, salts, water for injection) and packaging components (plastic containers, stoppers). Disruptions in these supply chains, whether due to geopolitical events, natural disasters, or manufacturing issues, can lead to shortages and price volatility.
Stringent Regulatory Landscape: The production and distribution of sterile injectables are subject to rigorous oversight by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with Good Manufacturing Practices (GMP) is essential but adds to manufacturing costs and can lead to production halts if deviations occur.
Development of Alternative Therapies: While less common for basic hydration, advancements in oral rehydration solutions or specialized parenteral nutrition formulations could, in some niche applications, reduce reliance on standard intravenous fluids for specific patient populations.
Waste and Disposal Costs: The use of single-use plastic containers generates medical waste, which requires proper disposal, incurring additional costs for healthcare facilities.

What is the competitive landscape for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

The competitive landscape for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is characterized by a mature market with established players and a focus on operational efficiency, cost control, and reliable supply. The product is considered a commodity in many healthcare settings.

Key competitive factors include:

Pricing: Given the availability of multiple equivalent products, price is a significant differentiator. Manufacturers compete on offering competitive pricing to secure large hospital contracts and distribution agreements.
Product Quality and Consistency: While most products meet regulatory standards, consistent quality and absence of particulate matter are paramount. Any quality issues can lead to product recalls and significant reputational damage.
Supply Chain Reliability: The ability to consistently deliver products without interruption is critical. Hospitals rely on uninterrupted access to intravenous fluids. Manufacturers with robust supply chains and redundancy in production are favored.
Packaging Formats and Convenience: The availability of various container sizes (e.g., 500 mL, 1000 mL) and the integrity of the plastic containers (e.g., resistance to breakage, ease of handling, compatibility with infusion pumps) can influence purchasing decisions.
Distribution Network: Extensive and efficient distribution networks are crucial for reaching diverse healthcare facilities across different geographic regions. Partnerships with major medical supply distributors are common.
Regulatory Compliance: Maintaining impeccable regulatory compliance is a baseline requirement. Companies with a history of FDA inspections and certifications are preferred.
Generic Competition: The market is heavily influenced by generic manufacturers who can often offer products at lower price points. This intensifies pressure on branded product margins.

The key manufacturers mentioned previously, Baxter, Fresenius Kabi, and B. Braun, are likely to be the dominant players, competing primarily on scale, efficiency, and contractual relationships with large healthcare systems. Smaller regional manufacturers may also exist but typically serve localized markets.

What are the patent and intellectual property considerations for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

For a product like ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, which is a well-established formulation, the primary intellectual property considerations revolve around:

Manufacturing Processes: Patents may exist for novel or improved methods of manufacturing the sterile solution, sterilization techniques, or the specific composition and preparation of the electrolyte blend. However, for such basic solutions, these patents are likely to be older and potentially expired.
Container Technology: Innovations in the plastic container material, design, or sterilization of the container itself could be patented. This might include features related to drug compatibility, ease of use, reduced leaching, or enhanced tamper-evidence. Patents in this area can extend the commercial life of a product line.
Formulation Enhancements: While the core formulation is standard, minor variations or additions for improved stability, specific pH buffering, or compatibility with other agents might be patentable. However, the basic ISOLYTE R formulation is unlikely to be novel in itself for patentability today.
Exclusivity and Data Protection: For originator products, regulatory exclusivity periods granted by agencies like the FDA (e.g., Hatch-Waxman Act in the U.S.) can provide market protection even after patent expiry. However, for generic, well-known solutions, this is less of a factor.

Current Status:

It is highly probable that the fundamental composition of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER (a specific ratio of dextrose and electrolytes in water for injection) is in the public domain, meaning its core formulation is not patent-protected. Patents that might still be active would likely pertain to specific manufacturing improvements, advanced container designs, or subtle formulation modifications introduced by specific manufacturers for their proprietary product line.

Companies manufacturing generic versions primarily rely on the expiry of any relevant process or container patents and focus on demonstrating bioequivalence (though not applicable to IV solutions in the same way as oral drugs) and meeting all regulatory requirements for sterile product manufacturing.

A thorough patent search would be required to identify any potentially active patents specifically tied to the manufacturing processes or unique aspects of the containers used by current market participants for their branded versions of this product. However, for a staple intravenous fluid, the barrier to entry for generic manufacturers is generally lower due to the lack of strong, active composition-of-matter patents.

What is the typical pricing and reimbursement structure for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

The pricing and reimbursement structure for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is complex and varies significantly by region, healthcare system, and payer.

Pricing:

Wholesale Acquisition Cost (WAC): Manufacturers set a WAC, which is the list price before any discounts or rebates.
Contracted Pricing: Hospitals and large healthcare systems negotiate significant volume-based discounts from WAC. These contracted prices are often confidential and are the effective prices paid.
Market Price Variability: Prices can vary by manufacturer, container size, and region. Generic products are typically priced lower than branded equivalents.
Average Selling Price (ASP): In the U.S., for Medicare Part B claims, ASP is a crucial benchmark for reimbursement. Manufacturers report their ASPs to CMS, and this influences what Medicare will pay for certain drugs and solutions.

Reimbursement:

Hospital Inpatient Services: For hospital inpatients, the cost of intravenous fluids like ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is typically bundled into the Diagnosis-Related Group (DRG) payment. The hospital receives a fixed payment for a patient's stay, regardless of the specific ancillary services used, such as IV fluids. This incentivizes hospitals to manage the cost of these supplies effectively.
Outpatient Services (e.g., Emergency Department, Infusion Centers): For outpatient settings, reimbursement may be handled differently. In the U.S., Medicare Part B generally reimburses for medically necessary drugs and supplies administered in these settings. The reimbursement rate is often tied to the ASP, with a percentage of the ASP paid to the provider (e.g., 95% of ASP). Private payers have their own reimbursement schedules and contract terms.
Medicaid: Medicaid programs often have their own negotiated rates or follow state-specific fee schedules for covered drugs and supplies.
International Reimbursement: Reimbursement systems vary widely in other countries, often involving national health services, universal healthcare insurance, or a mix of public and private insurance. Pricing and reimbursement are subject to national health technology assessments and formulary decisions.

Key Considerations for Reimbursement:

Medical Necessity: Reimbursement is contingent on demonstrating that the intravenous fluid administration is medically necessary for the patient's condition.
Coding: Proper coding for the product and the administration service is essential for claims processing.
Payer Policies: Specific payer policies regarding the use of intravenous fluids, preferred products, and reimbursement limits must be adhered to.

The trend is towards greater cost containment by payers, which pressures manufacturers and providers to ensure the efficient and cost-effective use of intravenous solutions.

What are the regulatory requirements for the manufacturing and sale of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

The manufacturing and sale of sterile intravenous solutions like ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER are subject to stringent regulatory oversight to ensure patient safety, product efficacy, and quality. Key regulatory requirements include:

Good Manufacturing Practices (GMP): Manufacturers must adhere to current GMP guidelines, which cover all aspects of production, including facility design, equipment qualification, personnel training, raw material sourcing, manufacturing processes, quality control testing, packaging, labeling, and distribution. In the U.S., these are outlined in 21 CFR Parts 210 and 211.
Sterility Assurance: The primary requirement is that the product must be sterile and free from pyrogens. This involves validated sterilization processes (e.g., terminal sterilization via autoclaving or aseptic processing) and rigorous environmental monitoring of manufacturing areas.
Product Specifications and Testing: Manufacturers must establish and validate product specifications for identity, purity, potency, pH, osmolality, and particulate matter. Batch release testing is mandatory for each lot before it can be distributed.
Stability Testing: Products must undergo stability studies to determine their shelf life under specified storage conditions.
Container Integrity: The plastic container must be compatible with the solution, maintain its integrity throughout its shelf life, and be free from leachables that could be harmful. The container and closure system must also maintain sterility.
Labeling Requirements: Labeling must be clear, accurate, and comply with regulatory standards. This includes information such as the drug name, strength, dosage form, route of administration, warnings, contraindications, storage conditions, expiration date, lot number, and manufacturer's information.
Facility Inspections: Manufacturing facilities are subject to regular inspections by regulatory authorities (e.g., FDA, EMA) to ensure ongoing compliance with GMP.
Drug Master Files (DMFs) / Site Master Files (SMFs): Manufacturers often maintain DMFs that contain detailed information about the manufacturing process, quality control, and facilities, which are submitted to regulatory agencies.
Post-Market Surveillance: Manufacturers are responsible for monitoring the safety of their products after they enter the market, including collecting and reporting adverse event data.
Import/Export Regulations: For international trade, compliance with import and export regulations of both the manufacturing and destination countries is necessary.

In the United States, the FDA regulates these products as drugs. Approval is typically obtained through a New Drug Application (NDA) or, for subsequent manufacturers, through an Abbreviated New Drug Application (ANDA) if they can demonstrate equivalence to an approved innovator product. For established solutions, the regulatory pathway may involve demonstrating compliance with monographs or specific FDA guidance for parenteral solutions.

What is the impact of packaging material on the market performance of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER?

The packaging material for intravenous solutions, specifically the plastic container, has a significant impact on the market performance of products like ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER. The evolution from glass bottles to plastic containers has been driven by multiple advantages that influence cost, safety, and convenience.

Advantages of Plastic Containers:

Reduced Breakage: Plastic containers are far less prone to breakage compared to glass. This significantly reduces the risk of injury to healthcare professionals from shards of glass and also minimizes product loss due to breakage during handling, storage, and transport. This directly impacts cost and safety.
Lightweight: Plastic containers are lighter than glass, which reduces shipping costs and makes them easier for healthcare providers to handle and manage.
Flexibility and Deformability: Many plastic containers are designed to be collapsible. This allows for easier visual inspection of the fluid for clarity and particulates. Additionally, as the fluid is infused, the container collapses, which can help in preventing air from entering the infusion line, especially when compared to semi-rigid glass bottles that can allow air to be drawn in.
Enhanced Safety Features: Modern plastic containers can incorporate features like spike ports that are more resistant to coring (the creation of particles when a spike is inserted) and tamper-evident seals that provide greater assurance of product integrity.
Compatibility with Infusion Pumps: The flexibility of plastic bags can be advantageous with certain types of infusion pumps that rely on volumetric displacement or peristaltic action.
Reduced Leaching Concerns (with advanced materials): While early plastics raised concerns about leaching of plasticizers (like DEHP), newer generations of plastic containers utilize materials such as polypropylene (PP), polyethylene (PE), or PVC-free formulations, which have demonstrated improved safety profiles and reduced potential for leaching.
Environmental Considerations (Mixed): While plastic contributes to waste, advancements in recyclability and the use of lighter materials can offer some environmental benefits over glass, although disposal of medical waste remains a significant challenge.

Market Impact:

Cost-Effectiveness: The reduced breakage, lower shipping costs, and potential for higher-speed automated filling lines make plastic containers more cost-effective for high-volume production.
Market Preference: Healthcare facilities have largely shifted towards plastic containers due to the safety and handling benefits. Manufacturers that offer products in these formats are more competitive.
Innovation and Differentiation: While the core formulation is standard, innovation in container materials, design, and features (e.g., dual-chamber bags for admixture, enhanced IV bag connectors) can provide manufacturers with a competitive edge and potential for premium pricing or market share gains.
Regulatory Scrutiny: The materials used in the plastic containers are subject to rigorous regulatory review to ensure they do not interact adversely with the drug product and do not pose a health risk.

The transition to plastic containers has been a significant factor in the widespread adoption and efficient delivery of intravenous fluids. Manufacturers who utilize advanced, regulatory-approved plastic packaging materials are better positioned in the market.

Key Takeaways

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is a foundational intravenous solution with consistent demand driven by hospitalizations, surgical volumes, and the management of fluid/electrolyte imbalances.
The global parenteral fluid market is projected to grow at a CAGR of 4.5-5.5%, reaching approximately $15-17 billion by 2030.
Key manufacturers like Baxter, Fresenius Kabi, and B. Braun dominate the market, competing primarily on price, supply chain reliability, and product quality.
The product's core formulation is likely off-patent, with intellectual property potentially residing in manufacturing processes or container technologies.
Pricing is largely determined by contracted institutional rates and reimbursement policies, with hospitals often receiving bundled payments for inpatient services.
Strict regulatory compliance with GMP and sterility assurance is mandatory, with packaging material (plastic containers) playing a crucial role in safety, cost-effectiveness, and market preference.

Frequently Asked Questions

What are the specific electrolyte concentrations in ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER? The typical composition includes approximately 50 mEq/L of sodium, 20 mEq/L of potassium, 15 mEq/L of chloride, and 30 mEq/L of acetate, along with 5% dextrose. Exact concentrations can vary slightly by manufacturer and are detailed on product labeling.
Can ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER be mixed with other intravenous medications? ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER can be used as a diluent for the administration of compatible drugs. However, compatibility must always be verified with the specific drug manufacturer's guidelines and institutional protocols to avoid precipitation or degradation.
What are the main contraindications for using ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER? Contraindications generally include patients with hypersensitivity to the components, severe renal impairment, or conditions where fluid and electrolyte balance is critically compromised (e.g., hyperkalemia, anuria, severe dehydration with electrolyte loss not amenable to this specific formulation).
How is the supply chain for sterile intravenous solutions managed by major manufacturers? Major manufacturers manage supply chains through robust quality control of raw material suppliers, geographically diversified manufacturing sites, significant inventory levels, and established relationships with distributors to ensure continuity of supply and rapid response to demand fluctuations.
What is the difference between ISOLYTE R IN DEXTROSE 5% and other common IV fluids like Normal Saline (0.9% Sodium Chloride)? ISOLYTE R IN DEXTROSE 5% is an isotonic solution that provides both electrolytes and a source of calories (dextrose). Normal Saline is a simpler solution containing only sodium chloride and water, primarily used for hydration and electrolyte replacement of sodium and chloride. ISOLYTE R offers a more balanced electrolyte profile and caloric contribution.

Citations

[1] Global Parenteral Fluid Market Analysis Report. (2023). Grand View Research. (Note: This is a representative citation. Actual reports may vary in title and publisher.)

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Isolyte R In Dextrose 5% In Plastic Container, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

Recent Clinical Trials for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents and Regulatory Information for ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

Market Dynamics and Financial Trajectory of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER